Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market

Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it has received notification from The NASDAQ Stock Market LLC® that BioSante's common stock is approved for listing on The NASDAQ Global Market. BioSante's board of directors approved the decision to switch the listing of BioSante's common stock from The American Stock Exchange to The NASDAQ Stock Global Market LLC®. BioSante currently is going through all the required regulatory processes associated with the switch and expects its common stock to begin trading on NASDAQ under the symbol BPAX in early to mid-November 2007. BioSante's common stock will continue to trade on the American Stock Exchange under its current symbol BPA until such date.

BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market

LINCOLNSHIRE, IL | Posted on October 23rd, 2007

"This decision was reached after careful consideration of capital market alternatives and an analysis of the electronic market model, which provides increased visibility and liquidity to our investors," said Stephen M. Simes, BioSante's president and chief executive officer. "We wish to thank The American Stock Exchange as well as our specialist on AMEX, Cohen Specialists, for the years of support and orderly trading."

"We believe that NASDAQ's electronic multiple market maker structure will provide BioSante with enhanced exposure and liquidity, while at the same time provide investors with the fastest execution and lowest cost per trade," said Phillip Donenberg, BioSante's chief financial officer. "This makes the move to NASDAQ a logical step and we expect a very orderly transfer."

About NASDAQ

NASDAQ® is the largest U.S. electronic stock market. With approximately 3,200 companies, it lists more companies and, on average, its systems trade more shares per day than any other U.S. market. NASDAQ is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ website at http://www.nasdaq.com or the NASDAQ NewsroomSM at http://www.nasdaq.com/newsroom .

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine. Additional information is available online at http://www.biosantepharma.com .

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include the anticipated timing of the trading of BioSante’s common stock on The NASDAQ Global Market, the effect of such listing on BioSante, its common stock and investors, and the expectation of an orderly transfer to NASDAQ from the American Stock Exchange. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the ability of BioSante to continue to satisfy initial listing requirements of The Nasdaq Global Market, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, the success of clinical testing, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014

Nanomedicine

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Announcements

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

University of Waterloo Visits China to Strengthen Bonds With Research Partners April 21st, 2014

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE